anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Tobramycin inhalation solution, USP should be stored under refrigeration at 2ºC to 8ºC/36ºF to 46ºF. Upon removal from the refrigerator, or if refrigeration is unavailable, tobramycin inhalation solution, USP pouches (opened or unopened) may be stored at room temperature (up to 25ºC/77ºF) for up to 28 days. Tobramycin inhalation solution, USP should not be used beyond the expiration date stamped on the ampule when stored under refrigeration (2ºC to 8ºC/36ºF to 46ºF) or beyond 28 days when stored at room temperature (25ºC/77ºF).

Tobramycin inhalation solution, USP ampules should not be exposed to intense light. The solution in the ampule is colorless to light yellow, but may darken with age if not stored in the refrigerator; however, the color change does not indicate any change in the quality of the product as long as it is stored within the recommended storage conditions.

FOR YOUR PROTECTION:Do not use if ampule appears damaged.
This is a Phase 1, Open-Label Safety Study of Escalating Doses of Intracerebroventricular Injections of Ex Vivo Expanded, Autologous Adipose-Derived Stem Cells (ADSCs) in Participants with Mild to Moderate Alzheimer's Disease (AD) whose Treatment is not Addressed Adequately by Available Therapy (i.e., an unmet medical need). The investigational product, which is referred to as RB-ADSC, consists of stem cells obtained from the participant's own adipose tissue by lipoaspirate. After collection, the stem cells are cultured and expanded outside the body, and then reintroduced into the same patient. A soft plastic reservoir (Ommaya reservoir) is implanted under the scalp, communicating with the brain cavities (ventricles). This study will primarily evaluate the safety of RB-ADSC injected in the Ommaya reservoir in a 3 + 3 dose escalation study. The planned enrollment will be 9 participants, 3 participants per escalation Cohort.

The primary objectives will evaluate adverse events, serious adverse events, and dose limiting toxicities to determine a recommended phase 2 clinical trial dose. Secondary objectives will evaluate preliminary efficacy measured by clinical assessments, volumetric MRI (Neuro Quant®), CSF biomarkers (Phospho-Tau, Total Tau, AB-42), and diagnostic imaging comparison (Amyloid PET). Each participant will be followed for 12 months after treatment.
Weight loss is important to improve overall health and reduce risk of obesity-related comorbidities such as diabetes. Numerous studies performed on individuals with predisposed genetic propensity to obesity who are deemed to be metabolically 'thrifty', require further structured intensification of caloric restriction and change in physical activity in order to achieve weight loss. Whether greater weight loss is as a result of smaller reduction in energy expenditure with calorie restriction is not known. Resting energy expenditure and 24-hour energy expenditure vary substantially between individuals. Obese individuals that lose weight experience a decrease in 24-h EE and resting energy expenditure that is lower than predicted based on changes in body composition. Most weight loss studies have found a large individual variation in the amount of weight change, and whether an individual's response to an intervention can be predicted is not clear. Measurements of 24-hour EE in response to fasting may help predict weight loss. The ECAL indirect calorimeter (ECAL) is a validated device purpose-built to provide the practitioner and patient with energy information that allows for more accurate, reliable method of establishing an obese individuals' metabolic profile. The ECAL device also measures the respiratory quotient (RQ) which is the ratio of the volume of carbon dioxide expired to that of oxygen consumed by the individual for every breath. Previous studies demonstrated variability in role of RQ in predicting weight loss, but individuals who demonstrated an RQ in the lower range (\<0.72) were more likely to maintain the weight-loss achieved on a caloric restriction and avoid a weight loss rebound as compared to those with RQ in the higher range (\>0.75). This suggests that RQ could prove useful in clinical practice as a prognostic marker for long-term effectiveness of low- and very-low-calorie diets used to induce weight loss. Baltimore Longitudinal Study on Aging shared a similar finding that fasting RQ or respiratory exchange ratio adjusted for age, BMI, and fat free mass was positively related to weight change. The aim of this study is to determine whether providing energy information from ECAL indirect calorimeter as an adjunct to the multicomponent weight management intervention in non-diabetic obese and severely obese individuals would help predict the response of weight loss.
White adipose tissue (WAT) plays a pivotal role in the onset of type 2 diabetes mellitus (T2DM) and obesity. Despite its significance the underlying pathogenesis and key genes associated with it remain elusive. In our study, we screened the differentially expressed genes (DEGs) in intra-abdominal WAT of T2DM patients with obesity, as well as those with simple obesity, aiming to lay a foundational theory for an in-depth investigation of T2DM pathogenesis and the identification of novel therapeutic targets. Gene expression datasets (GSE16415 and GSE71416) were retrieved from the Gene Expression Omnibus (GEO) database. We employed R for screening DEGs and conducted a functional enrichment analysis using the Metascape database. Combined Lasso regression and Boruta feature selection algorithms were used to identify key DEGs. Subsequently, these were cross-verified using the GSE29231 dataset. Samples and medical records were collected from clinical study participants. The mRNA and protein expressions of the key DEGs were verified using qRT-PCR and western blotting, respectively. We discerned a total of 130 DEGs, with 40 being upregulated and 90 downregulated. Functional and pathway enrichment analyses illuminated that these genes are instrumental in mediating metabolite and energy production, neutrophil-mediated immunity, and other associated biological processes. This includes their involvement in the tricarboxylic acid cycle, glycolysis/gluconeogenesis, peroxisome proliferator-activated receptors, and other signalling pathways. Two genes, CIDEA and FSCN1 emerged as key DEGs. The low expression of CIDEA and high expression of FSCN1 in the T2DM and obesity group were verified in clinical samples (P < 0.05). We established that CIDEA and FSCN1 manifest significant differential expression in T2DM patients who are obese. This suggests their potential as risk assessment markers and therapeutic targets for T2DM.
An increased incidence of seizures has been reported in patients with a history of epilepsy who received the related drug amantadine. In clinical trials of rimantadine hydrochloride, the occurrence of seizure-like activity was observed in a small number of patients with a history of seizures who were not receiving anticonvulsant medication while taking rimantadine hydrochloride. If seizures develop, rimantadine hydrochloride should be discontinued. 

The safety and pharmacokinetics of rimantadine in hepatic insufficiency have only been evaluated after single dose administration. In a study of 14 subjects with chronic liver disease (mostly stabilized cirrhotics), no alterations in the pharmacokinetics were observed after the administration of a single dose of rimantadine. However, the apparent clearance of rimantadine following a single dose to 10 patients with severe liver dysfunction was 50% lower than reported for healthy subjects. Because of the potential for accumulation of rimantadine and its metabolites in plasma, caution should be exercised when patients with hepatic insufficiency are treated with rimantadine. 

Following multiple-dose administration of rimantadine, there were no clinically relevant differences in rimantadine systemic exposure between subjects with mild or moderate renal impairment compared to healthy subjects. In subjects with severe renal impairment, rimantadine systemic exposure increased by 81%, compared with healthy subjects. Because of the potential for increased accumulation of rimantadine metabolites in renally impaired subjects, caution should be exercised when these patients are treated with rimantadine.

Transmission of rimantadine resistant virus should be considered when treating patients whose contacts are at high risk for influenza A illness. Influenza A virus strains resistant to rimantadine can emerge during treatment and such resistant strains have been shown to be transmissible and to cause typical influenza illness (Ref. 3). Although the frequency, rapidity, and clinical significance of the emergence of drug-resistant virus are not yet established, several small studies have demonstrated that 10% to 30% of patients with initially sensitive virus, upon treatment with rimantadine, shed rimantadine resistant virus. (Ref. 3, 4, 5, 6) 

Clinical response to rimantadine, although slower in those patients who subsequently shed resistant virus, was not significantly different from those who did not shed resistant virus. (Ref. 3) No data are available in humans that address the activity or effectiveness of rimantadine therapy in subjects infected with resistant virus. 

Serious bacterial infections may begin with influenza-like symptoms or may coexist with or occur as complications during the course of influenza. Rimantadine hydrochloride has not been shown to prevent such complications.
Chagas disease is a vector-borne parasitic infection affecting an estimated 6 million people worldwide. Very few people have been able to access antiparasitic treatment for the disease, and about 20% of those who do initiate treatment are unable to complete it due to the long duration (2 months) and side effects associated with the current regimen. Benznidazole is one of only two drugs with proven efficacy against Trypanosoma cruzi, the parasite that causes the disease. An earlier Phase 2 clinical trial, BENDITA, indicated 89% of 30 patients treated with a shorter (2-week) regimen of benznidazole maintained sustained parasite clearance after 12 months of follow-up, with no discontinuations of treatment due to side effects. The current study will evaluate shorter treatment regimens with benznidazole in a Phase III clinical trial. NuestroBen will assess the efficacy and safety of 2-week and 4-week regimens of BZN (300 mg daily), compared to the standard treatment of BZN 300 mg daily for 8 weeks, in terms of reducing and eliminating the T. cruzi parasite in adults in the chronic phase of Chagas disease with the indeterminate form or mild cardiac progression. Efficacy will be measured through conversion from positive to negative parasitaemia according to the results of qualitative PCR tests from the end of treatment, and up to 12 months of follow-up from the end of treatment. Safety will be compared according to the frequency and severity of adverse events. Patients adherence to treatment in each study arm will also be described.
PURPOSE:To obtain the titled slow-releasing agent by supporting a peptide having growth-promoting activity or osteometabolism-relating action on a low- toxic carrier decomposable in living body and administrable to body, such as a specific protein, polymeric saccharide, etc. CONSTITUTION:A growth-promoting peptide (e.g. growth hormone) or a peptide having osteometabolism-relating action (e.g. calcitonin) is supported on a carrier consisting of a mixture of one or more substances decomposable in living body, administrable to the body and having low toxicity, e.g. a protein such as collagen, gelatin, albumin, etc., a polymeric saccharide such as chitin, a synthetic polymer such as polylactic acid, polyglycolic acid, polyglutamic acid, etc. The product is formed in the form of an injectable suspension injection or a sphere, cylinder, needle, disk, etc., suitable for the part to be applied. It releases the growth-promoting component, etc., for a long period.
OBJECTIVES: Sleep disturbances in later life are prevalent and can profoundly impact health and well-being. However, whether and how trajectories of sleep disturbances vary as people age by gender and across age cohorts remains unexplored. This study applies an integrated theoretical framework to understand gender-specific trajectories of sleep disturbances over time and how they vary by cohort.
METHODS: Accelerated longitudinal data from the Health and Retirement Study (N = 20,947; M = 8,562, F = 12,385) was analyzed to investigate gender-specific trajectories of sleep disturbances and potential cohort variations. Weighted growth curve model was applied with sociodemographic and health-related variables. Men and women were analyzed separately.
RESULTS: Results showed that sleep disturbances increased with age in men, but not in women. Also, younger cohorts of men increased sleep disturbances over time at a slower rate than older cohorts. Among men, health profiles accounted for the association between age and sleep disturbances. Among men and women, younger cohorts started with higher levels of sleep disturbances around midlife. When examining specific types of sleep disturbance separately, having trouble falling asleep was the type that drove the observed patterns in men. For women, there was no association between age and any individual type of sleep disturbance.
DISCUSSION: This study shows that men, rather than women, tend to experience increasing sleep disturbances with age, with some variations across cohorts. These findings imply that different strategies for men and women and targeted timing over the life course would be most effective at promoting sleep health in American men and women.
Aim: The aim of the study is to investigate the relationship between femoral cartilage thickness and inflammatory parameters, pain severity and functionality in participants with Knee Osteoarthritis.

Methods: This study is designed as a prospective, cross-sectional trial. 90 participants aged between 50-65 years with knee osteoarthritis(OA) and at least 50 participants without any symptom for knee OA are included in the study in accordance with the inclusion criteria. Participants' demographic characteristics will be evaluated, and ultrasonographic measurement will be performed for measuring femoral cartilage thickness. Visual Analog scale will be used for pain severity and Western Ontario and McMaster Universities Osteoartrit index (WOMAC) will be used for assessing functionality of the patients. Also hematologic parameters(neutrophils, leucocytes, lymphocytes, platelet, CRP, erythrocyte sedimentation rate) will be evaluated for investigating the inflammation. The relationship between femoral cartilage thickness and inflammatory parameters, pain severity and functionality in knee osteoarthritis will be analysed for both group.
Subjects will have their thumb immobilized in 2 prefabricated wrist splints to simulate 2 different fusion positions tested: one splint to simulate the MCP fusion and one to represent the IP fusion. Patients will complete hand function tests in each of the splints to evaluate hand function.
The invention discloses a kind of extraction of turmeric and enrichment methods, belong to Natural Medicine Chemistry extractive technique neighborhood.The extraction of turmeric and enrichment method, include the following steps：1. the preparation of chitin nanometer；2. the crushing of medicinal material；3. the preparation of ionic liquid and chitin nanometer solution：Ionic liquid, 3 methylimidazole of bromination dodecyl, 200mM.Chitin nanometer, 200 μ g/mL；4. ionic liquid ultrasonic extraction：0.2g Turmeric Roots are added in 10mL ionic liquids in Ultrasound Instrument, the ultrasonic extraction 30min at 40 DEG C；5. chitin nanometer is enriched with：The turmeric ionic liquid extract liquid of 1.0mg/mL is enriched with 0.6 μ g/mL chitin nanometers；6. eluting solvent：Acetone.The method significantly reduce the use of organic solvent, the pollution and harm in extraction process are significantly reduced, extraction effect and extraction efficiency is improved, and this method is simple, has wide range of applications, easy to use, concentration effect is notable.
Eosinophilic pneumonia has been reported in patients receiving daptomycin for injection [see Adverse Reactions (6.2)]. In reported cases associated with daptomycin for injection, patients developed fever, dyspnea with hypoxic respiratory insufficiency, and diffuse pulmonary infiltrates or organizing pneumonia. In general, patients developed eosinophilic pneumonia 2 to 4 weeks after starting daptomycin for injection and improved when daptomycin for injection was discontinued and steroid therapy was initiated. Recurrence of eosinophilic pneumonia upon re-exposure has been reported. Patients who develop these signs and symptoms while receiving daptomycin for injection should undergo prompt medical evaluation, and daptomycin should be discontinued immediately. Treatment with systemic steroids is recommended.
Our intervention will be a 12-week personalised, VR-integrated physiotherapy intervention in which a selection of existing VR modules developed by our partners (i.e. Reducept and SyncVR) will be integrated into physiotherapy treatment. The following VR modules will be used: education (Reducept), relaxation and distraction (SyncVR Relax \& Distract), activation (SyncVR Fit). Patients will use the Pico Neo 3 VR headset at the physiotherapy practice and at home 5 days a week for 10-30 minutes. In addition, physiotherapists will help patients transition from movements performed in a VR context to daily activities without VR.
The present invention provides single-stranded circular oligonucleotides each with at least one parallel binding (P) domain and/or at least one corresponding anti-parallel binding (AP) domain separated from each other by loop domains. When more than one P or AP domain is included in a circular oligonucleotide of the present invention, the additional P or AP domains can constitute loop domains for a pair of corresponding P and AP domains, and vice versa. The present invention further provides single-stranded circular oligonucleotides with at least one Hoogsten anti-parallel (HAP) domain. Each P, AP and HAP domain has sufficient complementarity to bind to one strand of a defined nucleic acid target wherein the P domain binds in a parallel manner to the target and the HAP or AP domain binds in an anti-parallel manner to the target. Moreover, the present single-stranded circular oligonucleotides can bind to both single-stranded and double-stranded target nucleic acids. The present invention also provides methods of making and using these oligonucleotides as well as kits and pharmaceutical compositions containing these oligonucleotides.
PURPOSE:A gypsum dissolvent, containing a salt of ethylenediaminetetraacetic acid, carbonate and n-caproic acid, etc. as essential componens, capable of readily dissolving and removing sticking gypsum by dissolving this dissolvent in water and dipping a material to which the gypsum is sticking and useful for dental medical fields. CONSTITUTION:A gypsum dissolvent containing a salt of ethylenediaminetetraacetic acid, e.g. NH salt, Na salt or K salt, etc., a carbonate, e.g. NaHCO3, KHCO3, NH4HCO3, Na2CO3 or K2CO3, and at least one of cyclohexane-1,2-dicarboxylic acid, o-toluic acid, m-toluic acid, n-caproic acid, itaconic acid, 2,3-naphthalenedicarboxylic acid, phthalic acid or a salt thereof, e.g. alkali metal salt, as an active constituent. The resultant dissolvent may be dissolved in water and used by dipping a material to which gypsum is sticking in the resultant solution. EFFECT:The inhibition of reuse of machines and tools, etc., with sticking gypsum used for preparing artificial teeth can be prevented.
Prepn. of an extract of Capsicum, rich in capasaicin and other capsinoids, comprises:(i) treating whole Capsicum fructescens fruits at least once, with hexane under reflux and gentle stirring for 30-120 mins.; (ii) hot filtration to separate the hexane phase from the vegetable material, and opt. combination of the hexane phases;(iii) concn. followed by crystallisation at  -30 to -10 deg  C for 5-24 hrs.; (iv) isolation of the crystals which are opt. purified and titrated.  The capsicums are treated once or twice with boiling hexane of total vol. 5-20 (pref. 10) l/kg of fruit. The hexane extracts are conc. to give a solvent vol. of approx. 1(pref. 0.8-1.5) l/kg of fruit to be extracted. The crystals are washed with hexane or with another hydrophobic organic solvent, e.g. pentane or petroleum ether and cooled to crystallisation temp. Preparation of a stabilised soln. of capsicum extract in cetyl alcohol yields a capsinoid rich crystalline prod. which is dissolved in EtOH,  filtered to remove insol. impurities, and to which liq. cetyl alcohol is added at 60 deg C. After EtOH evapn.,  a 5% soln. of capsaicin in cetyl alcohol is obtd.
Immune thrombocytopenia (ITP) is most common in women during their reproductive years. When a low platelet count occurs for the first time during pregnancy, the differential diagnosis includes pregnancy-specific conditions. Although ITP is the most common cause of thrombocytopenia early in pregnancy, pregnancy-related thrombocytopenia develops mainly in late gestation. As maternal and neonatal outcomes are usually favourable, ITP per se is not a contraindication for pregnancy. We report the case with a literature review of patient with ITP, whose diagnosis was established in early pregnancy. This condition was refractory to first-line treatments, such as high-dose steroids and intravenous immunoglobulin and other splenectomy-sparing approaches, as rituximab, having the control been reached on the third trimester after splenectomy. Although not effective in this case, we still believe that rituximab should be considered before surgery during pregnancy.
This retrospective cohort study aimed to identify the risk factors associated with postoperative wound infections in patients undergoing open reduction and internal fixation for tibial plateau fractures. The study was conducted between January 2019 and December 2022, with stringent inclusion and exclusion criteria. Data were collected from the Electronic Health Record system, including demographic information, lifestyle habits, comorbid conditions and surgical variables like preoperative American Society of Anesthesiologists (ASA) scores. The IBM Statistical Package for the Social Sciences, version 27.0, was utilized for rigorous statistical analyses. Univariate analysis identified several factors, such as body mass index (BMI), smoking status and diabetes mellitus, as significant predictors of postoperative wound infection. Multivariate logistic regression revealed that BMI, type of fracture (open vs. closed), surgery duration exceeding 150 min, preoperative albumin levels below 35 g/L and preoperative ASA score of 3 or higher were significant independent risk factors (p < 0.05). Patients with open fractures, preoperative malnutrition, elevated preoperative ASA scores and a history of smoking are at a heightened risk of developing postoperative wound infections. Timely preoperative evaluation of these risk factors is crucial for minimizing the risk of surgical site infections and optimizing clinical management.